363 related articles for article (PubMed ID: 26773870)
1. The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium.
Dithmer M; Hattermann K; Pomarius P; Aboul Naga SH; Meyer T; Mentlein R; Roider J; Klettner A
Exp Eye Res; 2016 Apr; 145():187-205. PubMed ID: 26773870
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
3. Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2017 Jan; 154():39-46. PubMed ID: 27836572
[TBL] [Abstract][Full Text] [Related]
4. Intracellular pathways following uptake of bevacizumab in RPE cells.
Aboul Naga SH; Dithmer M; Chitadze G; Kabelitz D; Lucius R; Roider J; Klettner A
Exp Eye Res; 2015 Feb; 131():29-41. PubMed ID: 25533679
[TBL] [Abstract][Full Text] [Related]
5. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
Borchers L; Roider J; Klettner A
Ophthalmic Res; 2021; 64(3):369-388. PubMed ID: 33011724
[TBL] [Abstract][Full Text] [Related]
6. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
Ranjbar M; Brinkmann MP; Zapf D; Miura Y; Rudolf M; Grisanti S
Cell Physiol Biochem; 2016; 38(2):737-47. PubMed ID: 26871551
[TBL] [Abstract][Full Text] [Related]
7. Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation.
Deissler HL; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):83-94. PubMed ID: 30367290
[TBL] [Abstract][Full Text] [Related]
8. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2016 Feb; 143():49-59. PubMed ID: 26481553
[TBL] [Abstract][Full Text] [Related]
9. Transport and fate of aflibercept in VEGF-A
Deissler HL; Sommer K; Lang GK; Lang GE
Exp Eye Res; 2020 Sep; 198():108156. PubMed ID: 32712182
[TBL] [Abstract][Full Text] [Related]
10. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
Chae JB; Rho CR; Shin JA; Lyu J; Kang S
Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
[TBL] [Abstract][Full Text] [Related]
11. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.
Du S; Wang S; Wu Q; Hu J; Li T
Exp Eye Res; 2013 Nov; 116():151-60. PubMed ID: 24016866
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
Klettner A; Recber M; Roider J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
[TBL] [Abstract][Full Text] [Related]
13. Expression of neonatal Fc receptor in the eye.
Powner MB; McKenzie JA; Christianson GJ; Roopenian DC; Fruttiger M
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1607-15. PubMed ID: 24550358
[TBL] [Abstract][Full Text] [Related]
14. Pro-inflammatory activation changes intracellular transport of bevacizumab in the retinal pigment epithelium in vitro.
Hildebrandt J; Käckenmeister T; Winkelmann K; Dörschmann P; Roider J; Klettner A
Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):857-872. PubMed ID: 34643794
[TBL] [Abstract][Full Text] [Related]
15. Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung.
Sakagami M; Omidi Y; Campbell L; Kandalaft LE; Morris CJ; Barar J; Gumbleton M
Pharm Res; 2006 Feb; 23(2):270-9. PubMed ID: 16382279
[TBL] [Abstract][Full Text] [Related]
16. Basal and apical regulation of VEGF-A and placenta growth factor in the RPE/choroid and primary RPE.
Klettner A; Kaya L; Flach J; Lassen J; Treumer F; Roider J
Mol Vis; 2015; 21():736-48. PubMed ID: 26167115
[TBL] [Abstract][Full Text] [Related]
17. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis.
Klettner A; Tahmaz N; Dithmer M; Richert E; Roider J
Br J Ophthalmol; 2014 Oct; 98(10):1448-52. PubMed ID: 25034050
[TBL] [Abstract][Full Text] [Related]
18. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
Julien S; Biesemeier A; Taubitz T; Schraermeyer U
Br J Ophthalmol; 2014 Jun; 98(6):813-25. PubMed ID: 24457369
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
[TBL] [Abstract][Full Text] [Related]
20. Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey.
Hardiansyah D; Ng CM
Eur J Pharm Sci; 2018 Dec; 125():130-141. PubMed ID: 30248389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
